Acceleron Pharma Inc. (XLRN) Financial Statements (2025 and earlier)

Company Profile

Business Address 128 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2021
MRQ
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 849,903431,369291,312277,227139,690104,847
Cash and cash equivalents 670,952237,677144,052100,15020,95027,783
Short-term investments 178,951193,692147,260177,077118,74077,064
Receivables 26,1018,5477,0393,5703,2343,628
Other undisclosed current assets 17,26510,0007,6624,4463,8622,458
Total current assets: 893,269449,916306,013285,243146,786110,933
Noncurrent Assets
Operating lease, right-of-use asset 21,98823,908
Property, plant and equipment 7,7686,8127,1066,9665,2013,106
Long-term investments and receivables 7,58522,477 95,72394,69231,134
Long-term investments 7,58522,477 95,72394,69231,134
Restricted cash and investments   1,5971,132  
Other noncurrent assets 1,7271,79310511322368
Other undisclosed noncurrent assets     946796
Total noncurrent assets: 39,06854,9908,808103,934100,86135,404
TOTAL ASSETS: 932,337504,906314,821389,177247,647146,337
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 53,15327,19018,62816,02214,83913,275
Accounts payable 8,4722,2954191,0861,590875
Accrued liabilities 44,68124,89518,20914,93613,24912,400
Debt  6,183    
Deferred rent credit   284
Deferred revenue and credits7231,3101,216
Other undisclosed current liabilities 7,010     
Total current liabilities: 60,16333,37318,91216,74516,14914,491
Noncurrent Liabilities
Long-term debt and lease obligation: 17,06720,201    
Liabilities, other than long-term debt   2,3814,9794,6575,396
Deferred revenue and credits4,9794,6575,396
Deferred rent credit   2,381
Operating lease, liability 17,06720,201
Other undisclosed noncurrent liabilities (17,067)1,8561,4912,2361,24417,187
Total noncurrent liabilities: 17,06722,0573,8727,2155,90122,583
Total liabilities: 77,23055,43022,78423,96022,05037,074
Equity
Equity, attributable to parent 855,107449,476292,037365,217225,597109,263
Common stock 605347463934
Additional paid in capital 1,732,7721,160,807879,099839,090590,474416,926
Accumulated other comprehensive income (loss) (288)23(560)(895)(425)(220)
Accumulated deficit (877,437)(711,407)(586,549)(473,024)(364,491)(307,477)
Total equity: 855,107449,476292,037365,217225,597109,263
TOTAL LIABILITIES AND EQUITY: 932,337504,906314,821389,177247,647146,337

Income Statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 92,52373,99313,99113,48127,77118,097
Revenue, net12,94012,22116,913
Gross profit: 92,52373,99313,99113,48127,77118,097
Operating expenses (259,829)(210,438)(138,405)(123,464)(93,877)(78,976)
Operating loss: (167,306)(136,445)(124,414)(109,983)(66,106)(60,879)
Nonoperating income (expense) 1,29711,5255,5161,5619,116(3,015)
Investment income, nonoperating   5,5682,5531,854512
Other nonoperating income (expense) (1,576)819(52)(992)7,262(3,527)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes 920(2)22(10)(6)
Loss from continuing operations before equity method investments, income taxes: (166,000)(124,900)(118,900)(108,400)(57,000)(63,900)
Other undisclosed income (loss) from continuing operations before income taxes (9)(20)2(22)10 
Loss from continuing operations before income taxes: (166,009)(124,920)(118,898)(108,422)(56,990)(63,900)
Income tax expense (benefit) (21)6227(32)(24) 
Loss from continuing operations: (166,030)(124,858)(118,871)(108,454)(57,014)(63,900)
Loss before gain (loss) on sale of properties:(166,030)(124,858)(118,871)(108,454)(57,014)(63,900)
Net loss: (166,030)(124,858)(118,871)(108,454)(57,014)(63,900)
Other undisclosed net income attributable to parent      6
Net loss available to common stockholders, diluted: (166,030)(124,858)(118,871)(108,454)(57,014)(63,894)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (166,030)(124,858)(118,871)(108,454)(57,014)(63,900)
Comprehensive loss: (166,030)(124,858)(118,871)(108,454)(57,014)(63,900)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (311)583335(470)(205)(214)
Comprehensive loss, net of tax, attributable to parent: (166,341)(124,275)(118,536)(108,924)(57,219)(64,114)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: